Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.38 |
| ▸ | MERTK | Q12866 | 1/20 | 0.38 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | POLQ | O75417 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2134933 | 0.96 | SMN1; SMN2 (0.41) | CYP2A6FLT3TYRO3MERTKGAS6 | |
| SCHEMBL1505439 | 0.90 | CYP2A6 (0.40) | CYP2A6 | |
| SCHEMBL1505470 | 0.88 | CYP2A6 (0.39) | CYP2A6 | |
| SCHEMBL2132019 | 0.87 | CYP2A6 (0.38) | CYP2A6 | |
| SCHEMBL1505438 | 0.87 | CYP2A6 (0.38) | CYP2A6FLT3TYRO3MERTKGAS6 | |
| SCHEMBL2132176 | 0.86 | CYP2A6 (0.37) | CYP2A6 | |
| SCHEMBL2136593 | 0.86 | CYP2A6 (0.38) | CYP2A6FLT3TYRO3MERTKGAS6 | |
| SCHEMBL1505661 | 0.85 | CYP2A6 (0.39) | CYP2A6FLT3TYRO3MERTKGAS6 | |
| SCHEMBL2135477 | 0.85 | — | — | |
| SCHEMBL1505465 | 0.82 | CYP2A6 (0.43) | CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | UROD, UMPS, SLC14A1 | CYP2A6 754/4885FLT3 115/4885TYRO3 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.